{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:32Z","timestamp":1792441772724,"version":"4.5.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Nusinersen is an orphan drug intended for the treatment of spinal muscular atrophy (SMA), a severe genetic neuromuscular disorder. Considering the very high costs of orphan drugs and the expected market entry of cell and gene therapies, there is increased interest in the use of health technology assessment (HTA) for orphan drugs. This study explores the role of the economic evaluation and budget impact analysis on the reimbursement of nusinersen.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Appraisal reports for nusinersen were retrieved from reimbursement and HTA agencies in Belgium, Canada, France, England and Wales, Germany, Italy, Ireland, Scotland, Sweden, the Netherlands, and the United States. Detailed information was extracted on the economic evaluation, the budget impact, the overall reimbursement decision, and the managed entry agreement (MEA). Costs were adjusted for inflation and currency.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Overall, the reports included limited data on budget impact, excluding information on the sources of data for cost and patient estimates. Only three jurisdictions reported on total budget impact, estimated between 30 and 40\u00a0million euros per year. For early-onset SMA, the incremental cost-effectiveness threshold (ICER) ranged from \u20ac464,891 to \u20ac6,399,097 per quality-adjusted life year (QALY) gained for nusinersen versus standard of care. For later-onset SMA, the ICER varied from \u20ac493,756 to \u20ac10,611,936 per QALY. Although none of the jurisdictions found nusinersen to be cost-effective, reimbursement was granted in each jurisdiction. Remarkably, only four reports included arguments in favor of reimbursement. However, the majority of the jurisdictions set up an MEA, which may have promoted a positive reimbursement decision.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    There is a need for more transparency on the appraisal process and conditions included in the MEA. Additionally, by considering all relevant criteria explicitly during the appraisal process, decision-makers are in a better position to justify their allocation of funds among the rising number of orphan drugs that are coming to the market in the near future.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.750742","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:41:41Z","timestamp":1642736501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries"],"prefix":"10.3389","volume":"12","author":[{"given":"Alessandra","family":"Blonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Barcina Lacosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fphar.2021.630949","article-title":"Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review","volume":"12","author":"Abdallah","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B2","article-title":"Agenzia Italiana del Farmaco (AIFA)","volume-title":"Valutazione Dell\u2019Innovativit\u00e0 - Medicinale SPINRAZA","year":""},{"key":"B3","article-title":"Agenzia Italiana del Farmaco (AIFA)","volume-title":"Scheda Spinraza Approvata CTS 28.09","year":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","article-title":"Clinical trials in rare disease: challenges and opportunities","volume":"28","author":"Augustine","year":"2013","journal-title":"J. Child. Neurol."},{"key":"B4","unstructured":"Nusinersen (Spinraza\u00ae)2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/tmi.13138","article-title":"Stakeholder participation on the path to universal health coverage: the use of evidence-informed deliberative processes","volume":"23","author":"Baltussen","year":"2018","journal-title":"Trop. Med. Int. Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1843277","DOI":"10.1080\/20016689.2020.1843277","article-title":"Economic burden of spinal muscular atrophy: an analysis of claims data","volume":"8","author":"Belter","year":"2020","journal-title":"J. Mark Access Health Pol."},{"key":"B8","volume-title":"Guide for Patients with Spinal Muscular Atrophy and Their Caregivers Navigating Insurance and Support Programs for Spinraza\u00ae","author":"Biogen","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/fphar.2021.631527","article-title":"How to Value Orphan Drugs? A Review of European Value Assessment Frameworks","volume":"12","author":"Blonda","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0266462320000550","article-title":"Principles for deliberative processes in health technology assessment","volume":"36","author":"Bond","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B11","volume-title":"Kamerbrief over Voorwaardelijke Toelating Nusinersen","author":"Bruins","year":"2019"},{"key":"B12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","article-title":"Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy","volume":"172","author":"Burgart","year":"2018","journal-title":"JAMA Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/01.nt.0000558060.65287.46","article-title":"Two New Treatments for Spinal Muscular Atrophy May Be Clinically Effective, But Are They Cost-Effective?","volume":"19","author":"Butcher","year":"2019","journal-title":"Neurol. Today"},{"key":"B14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11940-014-0316-3","article-title":"Spinal Muscular Atrophy: Therapeutic Strategies","volume":"16","author":"Castro","year":"2014","journal-title":"Curr. Treat. Options. Neurol."},{"key":"B15","volume-title":"Application Number 209531Orig1s000 Medical Review(S)","year":"2016"},{"key":"B16","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Spinraza.2017"},{"key":"B17","article-title":"HSE to consider funding Spinraza as NHS approves muscle-wasting therapy","volume-title":"The Irish Times","author":"Coyle","year":""},{"key":"B18","first-page":"43","article-title":"Standard of Care for Spinal Muscular Atrophy","volume-title":"Disease Mechanisms and Therapy","author":"Crawford","year":"2017"},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462307051550","article-title":"Assessing the economic challenges posed by orphan drugs","volume":"23","author":"Drummond","year":"2007","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1023\/A:1012253723272","article-title":"Can parents rate their child's health-related quality of life? Results of a systematic review","volume":"10","author":"Eiser","year":"2001","journal-title":"Qual. Life Res."},{"key":"B114","volume-title":"Spinraza\u00ae and Zolgensma\u00ae for Spinal Muscular Atrophy: Effectiveness and Value-Final Evidence Report","author":"Ellis","year":"2019"},{"key":"B22","volume-title":"EPAR Summary for the Public: Spinraza","year":"2021"},{"key":"B24","first-page":"49","volume-title":"Proposal for a Regulation of the European Parliament and of the Council on Health Technology Assessment and Amending Directive 2011\/24\/EU COM\/2018\/051 Final - 2018\/018 (COD)","year":"2018"},{"key":"B25","volume-title":"Health technology Assessment Post 2020 - Consilium","year":"2021"},{"key":"B26","volume-title":"EMA\/410962\/2017 Rev 4. Guidance on Parallel Consultation","year":"2021"},{"key":"B23","volume-title":"Euro to Swedish Krona Spot Exchange Rates for 2019. Exchange Rates","year":"2021"},{"key":"B27","volume-title":"Hefty price set on a new drug that can stunt muscle disease","year":"2017"},{"key":"B28","article-title":"Internal Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII.","volume-title":"-Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Nusinersen (Exceeding \u20ac50 Million Turnover Limit: Spinal Muscular Atrophy","year":"2021"},{"key":"B29","volume-title":"How to Improve the Belgian Process for Managed Entry Agreements? an Analysis of the Belgian and International Experience","author":"Gerkens","year":"2017"},{"key":"B30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-021-01829-x","article-title":"Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)","volume":"16","author":"Gissen","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal Injections in Children with Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"J. Child. Neurol."},{"key":"B115","volume-title":"Avis d\u2019efficience Spinraza\u00ae (Nusinersen)","year":"2017"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1017\/S0266462317001064","article-title":"Analysis of duplication and timing of health technology assessments on medical devices in europe","volume":"34","author":"Hawlik","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/S13023-017-0676-3","article-title":"European Reference networks for rare diseases: what is the conceptual framework?","volume":"12","author":"H\u00e9on-Klin","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1750-1172-7-74","article-title":"Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?","volume":"7","author":"Hughes-Wilson","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"B35","unstructured":"Industry hopes dashed after EU compromises to squeeze through cross border HTA agreement2021"},{"key":"B36","article-title":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)","volume-title":"Nusinersen (5q-Assoziierte Spinale Muskelatrophie) \u2013 Bewertung Gem\u00e4\u00df \u00a7 35a Abs. 1 Satz 10 SGB V","year":"2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-3-319-67144-4_13","article-title":"Health Technology Assessment and Appraisal of Therapies for Rare Diseases","volume":"1031","author":"Iskrov","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","article-title":"Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy","volume":"227","author":"Jalali","year":"2020","journal-title":"J. Pediatr."},{"key":"B39","unstructured":"Vissa patienter med SMA kan f\u00e5 l\u00e4kemedlet Spinraza - Janusinfo.se2021"},{"key":"B40","unstructured":"Health technology assessment of orphan drugs The example of Pompe disease\n            KantersT. A.\n          2016"},{"key":"B41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/gt.2017.32","article-title":"New treatments for serious conditions: Ethical implications","volume":"24","author":"King","year":"2017","journal-title":"Gene Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMe030024","article-title":"Clinical Trials and Rare Diseases","volume":"348","author":"Lagakos","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/apa.14568","article-title":"A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy","volume":"108","author":"Landfeldt","year":"2019","journal-title":"Acta Paediatr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3406\/pharm.2004.5596","article-title":"Drugs under temporary use authorisation: 50 years of French drug development","volume":"52","author":"Launet","year":"2004","journal-title":"Rev. Hist. Pharm. (Paris)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s11136-014-0642-7","article-title":"The level of agreement between child self-reports and parent proxy-reports of health-related quality of life in boys with Duchenne muscular dystrophy","volume":"23","author":"Lim","year":"2014","journal-title":"Qual. Life Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","article-title":"Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain","volume":"12","author":"L\u00f3pez-Bastida","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1524-4733.2004.71273.x","article-title":"Assessment of Health-Related Quality of Life in Children: A Review of Conceptual, Methodological, and Regulatory Issues","volume":"7","author":"Matza","year":"2004","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/qjmed\/hcl033","article-title":"Orphan drugs revisited","volume":"99","author":"McCabe","year":"2006","journal-title":"QJM"},{"key":"B51","unstructured":"Spinraza, the exorbitantly priced SMA drug. Our complaint | Other consumption. Altroconsumo\n            MettaM.\n          2019"},{"key":"B52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/14737167.2016.1179116","article-title":"The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?","volume":"16","author":"Montgomery","year":"2016","journal-title":"Expert Rev. Pharmacoecon Outcomes Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1750-1172-8-198","article-title":"Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries","volume":"8","author":"Morel","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul. Disord."},{"key":"B60","volume-title":"Cost-Effectiveness of Nusinersen for the Treatment of 5q Spinal Muscular Atrophy","year":"2017"},{"key":"B61","volume-title":"Vervolgadvies Voorwaardelijke Toelating van Nusinersen (Spinraza\u00ae) Bij Pati\u00ebnten Met 5q Spinale Spieratrofie (SMA) Die 9,5 Jaar En Ouder Zijn","year":"2019"},{"key":"B62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","article-title":"Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group","volume":"21","author":"Nestler-Parr","year":"2018","journal-title":"Value Health"},{"key":"B63","volume-title":"Annual Average Exchange Rates of the Euro. Office of the commissioner for revenue","year":"2019"},{"key":"B64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"B55","volume-title":"Interim Process and Methods of the Highly Specialised Technologies Programme Updated to Reflect 2017 Changes","year":"2017"},{"key":"B65","unstructured":"Single Technology Appraisal-Nusinersen for treating spinal muscular atrophy [ID1069]-Committee7412018"},{"key":"B66","first-page":"30","volume-title":"Nusinersen for treating spinal muscular atrophy - technology appraisal guidance","year":"2019"},{"key":"B67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.healthpol.2017.03.009","article-title":"HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries","volume":"123","author":"Nicod","year":"2019","journal-title":"Health Policy"},{"key":"B68","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jval.2017.03.005","article-title":"Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries","volume":"20","author":"Nicod","year":"2017","journal-title":"Value Health"},{"key":"B69","volume-title":"Impact HTA | Health Technology Assessment | Country Vignettes","author":"Nicod","year":"2020"},{"key":"B70","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10198-016-0823-0","article-title":"Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries","volume":"18","author":"Nicod","year":"2017","journal-title":"Eur. J. Health Econ."},{"key":"B71","volume-title":"NT-r\u00e5dets yttrande till regionerna g\u00e4llande Spinraza (nusinersen) vid spinal muskelatrofi av typ 5q","year":"2019"},{"key":"B72","article-title":"F.D.A. Approval - The New York Times.","volume-title":"Costly Drug for Fatal Muscular Disease Wins","year":"2016"},{"key":"B73","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of spinal muscular atrophies","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","article-title":"Economic Modeling Considerations for Rare Diseases","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"key":"B76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/medethics-2011-100094","article-title":"A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation","volume":"38","author":"Pinxten","year":"2012","journal-title":"J. Med. Ethics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamapediatrics.2017.4360","article-title":"Nusinersen for spinal muscular atrophy: Are we paying too much for too little?","volume":"172","author":"Prasad","year":"2018","journal-title":"JAMA Pediatr."},{"key":"B78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpeds.2009.03.007","article-title":"Current Challenges and Future Research in Measuring Preferences for Pediatric Health Outcomes","volume":"155","author":"Prosser","year":"2009","journal-title":"J. Pediatr."},{"key":"B100","volume-title":"Gemotiveerd Definitief Voorstel - Weesgeneesmiddel 0149014801 SPINRAZA 12 Mg","year":""},{"key":"B101","volume-title":"Gemotiveerd Voorlopig Voorstel - Weesgeneesmiddel 0149014801 SPINRAZA","year":""},{"key":"B79","volume-title":"Evaluatierapport Dag 90 - Weesgeneesmiddel 0149014801 SPINRAZA","year":""},{"key":"B80","volume-title":"Overeenkomst K.B. 21.12.2001","year":"2018"},{"key":"B81","article-title":"Spinraza campaigners \u201cfinally have hope\u201d as HSE approves access to drug for rare disease","author":"Ryan","year":"","journal-title":"J."},{"key":"B82","article-title":"\u201cA price has been put on the value of life\u201d: HSE will not reimburse drug for children with rare condition","author":"Ryan","year":"2019","journal-title":"J."},{"key":"B83","article-title":"\u201cWe are failing these children spectacularly\u201d: Row over drug with \u201cexorbitant\u201d cost rumbles on","author":"Ryan","year":"2021","journal-title":"J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13023-016-0555-3","article-title":"Multi-criteria decision analysis (MCDA): Testing a proposed MCDA framework for orphan drugs","volume":"12","author":"Schey","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"33039","DOI":"10.3402\/jmahp.v4.33039","article-title":"Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement","volume":"4","author":"Schlander","year":"2016","journal-title":"J. Mark Access Health Pol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: The need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"B88","volume-title":"Scotland Opens Spinraza to All SMA Patients Using its Public Health System","year":"2019"},{"key":"B86","volume-title":"SMC Modifiers Used in Appraising New Medicines","year":"2012"},{"key":"B90","article-title":"Medicines advice: nusinersen (Spinraza)","volume-title":"Scottish Medicines Consortium (SMC)","year":""},{"key":"B91","article-title":"Nusinersen 12mg Solution for Injection (Spinraza \u00ae) - SMC No 1318\/18","volume":"1318","year":"2018"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2165\/00019053-200422170-00001","article-title":"Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall","volume":"22","author":"Stolk","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"B93","unstructured":"The World Bank Indicators. GDP deflator (base year varies by country)2021"},{"key":"B94","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff. Resour. Alloc"},{"key":"B89","volume-title":"Scotland will offer Spinraza treatment to all people with SMA \u2013 TreatSMA","year":"2021"},{"key":"B95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/S12687-021-00521-8","article-title":"European Reference Networks: challenges and opportunities","volume":"12","author":"Tumiene","year":"2021","journal-title":"J. Community Genet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","article-title":"Adjusting for Inflation and Currency Changes within Health Economic Studies","volume":"22","author":"Turner","year":"2019","journal-title":"Value Health"},{"key":"B97","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2165\/11591570-000000000-00000","article-title":"Challenges in health state valuation in paediatric economic evaluation: Are QALYs contraindicated?","volume":"29","author":"Ungar","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"B98","volume-title":"ODE-I Decisional Memorandum; NDA 209531-Nusinersen Office of Drug Evaluation-I","author":"Unger","year":"2016"},{"key":"B99","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10198-011-0346-7","article-title":"Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall","volume":"14","author":"van de Wetering","year":"2013","journal-title":"Eur. J. Health Econ."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40273-015-0311-x","article-title":"Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment","volume":"33","author":"van de Wetering","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"B103","volume-title":"Test-Aankoop dient klacht in tegen spierziektemedicijn: \u2018Overdreven duur.\u2019 De Morgen","author":"Vandekerckhove","year":"2019"},{"key":"B104","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Med. Care"},{"key":"B105","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J. Child. Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"B108","doi-asserted-by":"publisher","first-page":"E1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1478-4505-10-6","article-title":"Multi-criteria decision analysis for setting priorities on HIV\/AIDS interventions in Thailand","volume":"10","author":"Youngkong","year":"2012","journal-title":"Health Res. Pol. Syst."},{"key":"B110","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch. Neurol."},{"key":"B111","volume-title":"Pakketadvies Nusinersen (Spinraza\u00ae)","year":"2018"},{"key":"B112","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","article-title":"Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden","volume":"37","author":"Zuluaga-Sanchez","year":"2019","journal-title":"Pharmacoeconomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.750742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:42:25Z","timestamp":1642736545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.750742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":109,"alternative-id":["10.3389\/fphar.2021.750742"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.750742","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"750742"}}